AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call at 72 hours by discharge nurse navigator
Description: Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone call at 72 hours by discharge nurse navigator
Description: Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge
Description: A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
Study NCT03923790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational messages every other week
Description: The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
Study NCT03923790 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BP monitoring by QardioARM with periodic transmission of BP data
Description: Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is \< 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
Study NCT00215735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: debridement, dressing, and APC
Description: ebridement, dressing, and APC
Study NCT03656952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: a single oral dose of 200 mg PF-06700841
Study NCT03656952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching PF-06700841
Study NCT03656952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: a single oral dose of 400 mg moxifloxacin
Study NCT03018444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablet
Study NCT03018444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00567034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone
Description: 50mg naltrexone, 1 tablet a day for 12 weeks.
Study NCT00567034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose placebo, 1 capsule every day for 12 weeks
Study NCT01793623 — intervention group
Intervention type: OTHER
Intervention: atrial tissue
Description: retrieval of discarded atrial tissue
Study NCT02589054 — intervention group
Intervention type: OTHER
Intervention: Monitoring
Study NCT04664803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefecin Tab.
Study NCT02398240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
Study NCT04664803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cap.
Study NCT00926627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight \< 40 kg/90 lb)
Study NCT00926627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical preparation as the study drug, but without the active substance, administered b.i.d.
Study NCT02691117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garlic concentrate
Description: Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
Study NCT00834327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks
Study NCT00834327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aplindore MR tablets or Placebo
Description: aplindore MR tablets administered QD for about 4 weeks
Study NCT00875602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverOn (EarlySense) contactless monitoring device
Description: Hospitalized patients on the study unit are monitored by a contactless device
Study NCT04873739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anterior Segment OCT
Description: AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
Study NCT02883127 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motivational interviewing
Description: The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.~2. Eat mainly carbohydrates of low glycaemic index.~3. Reduce the intake of carbohydrate of high glycaemic index.~4. Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care.
Study NCT01540331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: model 1000 PNT vacuum controller (the vacuum device for ocular suction)
Description: A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
Study NCT00925132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, Decitabine, Panobinostat
Description: Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation.
Study NCT03748992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gNO
Description: This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires.
Study NCT03450226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stellate ganglion block
Description: After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
Study NCT05800418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab Injection
Description: Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
Study NCT05800418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab Injection [Cyramza]
Description: Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
Study NCT02963740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
Study NCT02963740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
Study NCT02963740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Phone Calls
Description: Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
Study NCT02448771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02448771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Study NCT02963740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
Study NCT01942785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: 2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
Study NCT04464785 — intervention group
Intervention type: DEVICE
Intervention: CentriMag Circulatory Support System
Description: The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
Study NCT02396628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
Study NCT02396628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
Study NCT00623701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allerslit forte
Description: sublingual placebo preparation, daily
Study NCT00623701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allerslit forte
Description: Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
Study NCT01927705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-AD Inj.
Study NCT00539435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Insulin on cardiac disease in diabetic pts
Description: Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Study NCT01637181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Description: EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
Study NCT00806156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 q14d
Description: NKTR-102 given on a q14 day schedule
Study NCT00806156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102 q21d
Description: NKTR-102 given on a q21 day schedule
Study NCT03558477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 1
Description: YYD601 1
Study NCT03558477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 2
Description: YYD601 2
Study NCT03558477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 3
Description: YYD601 3
Study NCT03558477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Nexium
Study NCT04393506 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Camrelizumab
Description: Inductive therapy with Camrelizumab of 200mg, iv, qd, on day 1, 15, 29.
Study NCT04393506 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Inductive therapy with Apatinib of 250mg, po, qd, initiating on day 1, ending on the fifth day before surgery.
Study NCT04393506 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical surgery
Description: Radical surgery will be performed on the 42th-45th after initiation of inductive therapy
Study NCT04393506 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Post-operative radiotherapy/chemoradiotherapy
Description: Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathologic diagnosis.
Study NCT04700449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind 0.2mg CBP-307
Description: 0.2 mg capsule oral administration
Study NCT04700449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Placebo
Description: Placebo capsule oral administration
Study NCT04700449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label CBP-307
Description: 0.2 mg capsule oral administration
Study NCT04700449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-Blind 0.1mg CBP-307
Description: 0.1 mg capsule oral administration
Study NCT02334371 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MR-PET
Description: The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
Study NCT01513551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine (V114)
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT01513551 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX® 23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
Study NCT01513551 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PREVNAR 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
Study NCT03699267 — intervention group
Intervention type: OTHER
Intervention: US-guided Bilateral TAP block
Study NCT01267266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study NCT01267266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hydrocortisone/placebo
Description: Given orally
Study NCT03565809 — intervention group
Intervention type: OTHER
Intervention: Incidence analysis
Description: Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
Study NCT03282240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-HD
Description: 0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
Study NCT03282240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed TIV-HD1
Description: 0.5 mL-dose was administered IM into the upper arm area.
Study NCT03282240 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigational TIV-HD2
Description: 0.5 mL-dose was administered IM into the upper arm area.
Study NCT03751059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac 0.07% Oph Susp
Description: Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
Study NCT03751059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
Study NCT02845843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Lopinavir /Ritonavir and Interferon beta-1b
Description: Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
Study NCT02845843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
Study NCT03242720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Ablation for Atrial Fibrillation
Description: Ablation of arrhythmia focus in the heart for atrial fibrillation
Study NCT03242720 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cardiac Ablation for Atrial Fibrillation
Description: Ablation of arrhythmia focus in the heart for atrial fibrillation
Study NCT02465853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Injection Hyaluronic Acid in the experimental group
Study NCT02465853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: Injection 0.9% Physiological saline solution\<1.0 ml
Study NCT02465853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and occupational therapy
Description: rehabilitation
Study NCT02465853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy and occupational therapy
Description: rehabilitation
Study NCT04227704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 50 MG/ML
Description: Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
Study NCT04227704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Administration of 0.9% Sodium Chloride (N/S)
Study NCT04227704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: Administration of 0.9% Sodium Chloride (N/S)
Study NCT00231803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined CKD and CVD Prevention
Description: Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
Study NCT00231803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular Disease prevention
Description: Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
Study NCT00231803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Chronic Kidney Disease complications
Description: Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
Study NCT00231803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No prescribed intervention, just those that the patient's own family physician thought indicated